1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 三唑核糖核苷和核糖核苷酸
• 英文名称: 1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide
• 化学式: C₈H₁₃N₅O₄
• 分子量: 243.22
• InChiKey: NHKZSTHOYNWEEZ-RGDLXGNYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  151
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
  申请人：——

  公开号：US20040077563A1

  公开（公告）日：2004-04-22

  A method of delivering a drug to a hepatocyte includes a step in which a carboxamidine group-containing compound is provided to a hepatocyte having a transporter that transports the compound across the plasma membrane of the hepatocyte, wherein the transport of the compound is substantially not inhibited by ribavirin. Further contemplated methods include a method of inhibiting growth of a virus of a family of flaviviridae in a cell containing system, in which contemplated compounds are presented to a cell in the cell containing system.

  一种向肝细胞递送药物的方法包括一个步骤，在该步骤中，向具有转运体的肝细胞提供含羧脒基团的化合物，该转运体可将化合物转运过肝细胞的质膜，其中化合物的转运基本上不受利巴韦林的抑制。进一步考虑的方法包括在含细胞系统中抑制黄病毒科病毒生长的方法，其中将考虑的化合物提供给含细胞系统中的细胞。
• Use of ribofuranose derivatives against inflammatory bowel diseases
  申请人：Brantl Victor

  公开号：US20050009766A1

  公开（公告）日：2005-01-13

  A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C 2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.

  本发明提供了一种预防或治疗炎症性肠病的方法，包括向患有炎症性肠病或有罹患炎症性肠病风险的患者施用治疗或预防有效量的一种或多种具有式（I）的核糖呋喃糖衍生物： 其中 R 是一个选自羧酰胺、脒及其药学上可接受的酸加成盐的基团，且在 C 2 一种或多种核呋喃糖衍生物（I）可与其他活性剂如抗病毒药或有效防治炎症性肠病的药物联合使用。
• METHODS OF DRUG DELIVERY TO HEPATOCYTES AND TREATMENT OF FLAVIVIRIDAE INFECTIONS
  申请人：Ribapharm, Inc.

  公开号：EP1313469A1

  公开（公告）日：2003-05-28
• Methods of treating gastrointestinal inflammation
  申请人：Raz Eyal

  公开号：US20070004654A1

  公开（公告）日：2007-01-04

  The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn's Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or that activates a Type I interferon signaling pathway in the individual.
• US6930093B2
  申请人：——

  公开号：US6930093B2

  公开（公告）日：2005-08-16